FSD Pharma Inc. Stock Company Profile
Information
199 Bay Street, Suite 4000
Toronto ON M5L 1A9
416 854 8884
www.fsdpharma.com
Industry: Drug Manufacturers—Specialty & Generic
Sector: Healthcare
Description
FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.
